Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02300350 · ClinicalTrials.gov registry record · Phase 1
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02300350 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT02300350, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple dose LX4211 (400 mg administered as 2 × 200-mg tablets qd × 12 days) on the PK of single-dose digoxin (2 × 0.25-mg tablets) in healthy male and female subjects.
Interventions
- DRUG Treatment A digoxin
- DRUG Treatment B LX4211
- DRUG Treatment C Digoxin + 400 mg LX4211 administered concomitantly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02300350
The ClinicalTrials.gov registry entry for NCT02300350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Treatment A digoxin is the first listed.
NCT02300350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02300350 about?
NCT02300350 is a clinical study titled "DDI Study With Multiple-dose LX4211 and Single Dose Digoxin". This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple dose LX4211 (400 mg administered as 2 × 200-mg tablets qd × 12 days) on the PK of single-dose digoxin (2 × 0.25-mg tablets) in healthy male and female...
What is the current status of trial NCT02300350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02300350?
The interventions under investigation include: Treatment A digoxin (DRUG), Treatment B LX4211 (DRUG), Treatment C Digoxin + 400 mg LX4211 administered concomitantly (DRUG).
Who is sponsoring clinical trial NCT02300350?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.